相关实验视频
Updated: Sep 12, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.8K
重新审视糖尿病中葡萄糖的作用:这都是坏事吗?
1Durham, NC.
概括
葡萄糖素,传统上被视为胰岛素的相反,也可能刺激胰岛素分泌,改善胰岛素敏感性. 这表明葡萄糖受体激动症可能是一种新的糖尿病治疗方法.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 葡萄糖传统上平衡胰岛素,通过刺激肝脏葡萄糖释放来预防低血糖症.
- 葡萄糖分泌量升高与导致高血糖和糖尿病的发展有关.
研究的目的:
- 研究葡萄糖素在传统功能之外的多方面的作用.
- 探索葡萄糖受体激动症作为糖尿病治疗策略的潜力.
主要方法:
- 对胰岛素诱导的低血糖和葡萄糖反应的临床研究的综述.
- 对肝细胞中葡萄糖信号传递的体外研究的分析.
- 对新型葡萄糖受体激动剂药物的临床试验数据的检查.
主要成果:
- 葡萄糖的作用扩展到刺激胰岛素分泌和增强肝脏胰岛素作用.
- 在被养和禁食状态下观察到的葡萄糖的不同作用.
- 临床试验显示,针对葡萄糖路的多受体药物具有前途.
结论:
- 传统的观点认为葡萄糖素仅仅是对胰岛素的逆调节作用是不完整的.
- 葡萄糖表现出复杂的功能,取决于代谢状态.
- 葡萄糖受体激动症为控制糖尿病提供了潜在的治疗途径.
相关概念视频
Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
Glucose Homeostasis: Regulation of Blood Glucose
2.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
2.5K
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263

